Author

Andreas Schall

Institution: Bayer (Germany)

Observed institution: Bayer (Germany)

OpenAlex ID: A5034423053

Design of SIRIUS: a randomized placebo-controlled Phase II study of inclocibart, an antibody against α2-antiplasmin, for proximal deep vein thrombosis

2026 · Jan Beyer-Westendorf, Dirk Thomas, et al. · TH Open

Effects of an ALK-1 kinase inhibitor on ocular leakage and neovascularization in rats

2016 · Michael Karl Boettger, Andreas Schall, et al. · Investigative Ophthalmology & Visual Science

Modern Drug Synthesis. Edited by Jie Jack Li and Douglas S. Johnson.

2010 · Andreas Schall, Helmut Haning · ChemMedChem

Works count: 3

Citation count:

H-index:

I10-index: